Shire plc News

Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder patch DaytranaA .

The NYSE Arca Pharmaceutical Index /quotes/comstock/10t!drg.x was virtually flat at 306.99 and the NYSE Arca Biotechnology Index /quotes/comstock/10t!btk.x was up marginally at 869.09. Shire shares were up almost 1% at $58.23. /quotes/comstock/15*!shpg.y Shire PLC /marketstate/country/ The market is open The market is closed $ 57.70 Change +1.27 ...

Shire plc , the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease .

News media are reporting that the U.S. Food and Drug Administration has issued warning letters to Shire PLC and Eisai Co Ltd about drug promotions for Dacogen and Fosrenol.

November 16, 2009 - Shire plc , the global specialty biopharmaceutical company, announced new study results on INTUNIV Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology .

U.S. regulators have warned Shire PLC and Eisai Co Ltd about drug promotions that minimized the medicines' risks and overstated benefits, letters released on Friday said.

Shire plc , the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse .

" Shire plc , the global specialty biopharmaceutical company, today announced the availability of INTUNIVTM Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents ages 6 to 17.

November 9, 2009 A- Shire plc , the global specialty biopharmaceutical company, today announced the availability of INTUNIVA Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents ages 6 to 17.

As Shire plc gears up for an early 2010 PDUFA date for its enzyme replacement therapy velaglucerase alfa in Gaucher's disease, potential competitor Protalix BioTherapeutics Inc.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/04/09, Medidata Solutions , a leading global provider of hosted clinical development solutions, announced a multi-year contract extension with Shire plc for use of Medidata Grants Manager and CRO Contractor benchmarking and analysis tools for ...

Medidata Solutions multiyear contract with Shire plc has been extended for use of Medidata Grants Manager and CRO Contractor benchmarking and analysis tools for investigator site and contract research organization trial budget planning and forecasting.

Shire plc, a global specialty biopharmaceutical company, today announced that the FDA has granted Priority Review for the New Drug Application for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.

DUBLIN, Ireland, November 2 Shire-plc DUBLIN, Ireland , November 2 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc announces that Mr David Stout joined the Board as a Non Executive Director with effect from 31 October 2009 .

Shire plc October 30, 2009 10:00 am ET Executives Eric Rojas a ' IR Angus Russell a ' CEO Graham Hetherington a ' CFO Analysts Tom Russo a ' Robert W. Baird & Co.

Shire plc , the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder .

Shire plc the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

Shares of biotechnology company Amicus Therapeutics Inc. fell Friday after the company said it ended a partnership with Shire PLC to jointly develop treatments for genetic disorders, while cutting jobs amid the resignation of its chief financial officer.

October 29, 2009 - Shire plc , the global specialty biopharmaceutical company, announced new study results on INTUNIV Extended Release Tablets, at a major psychiatric medical meeting today.

Shire plc today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL , paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease patients who are not on dialysis with a ...